We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $214M
1-Year Est. Return 62.74%
This Fund
S&P 500
This Quarter Est. Return
+5.78%
1 Year Est. Return
+62.74%
3 Year Est. Return
+258.24%
5 Year Est. Return
+582.22%
10 Year Est. Return
+8,737.07%
AUM
$82.5M
AUM Growth
+$17.6M
Cap. Flow
+$22.3M
Cap. Flow %
26.99%
Top 10 Hldgs %
81.1%
Holding
28
New
2
Increased
2
Reduced
Closed
1

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 79.11%
2 Miscellaneous 10.53%
3 Materials 4.76%
4 Industrials 2.96%
5 Financials 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALDX icon
1
Aldeyra Therapeutics
ALDX
$88.1M
$25.3M 30.67%
3,015,668
+948,508
+46% +$9.35M
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$10.8M 13.06%
450,422
AVDL
3
DELISTED
Avadel Pharmaceuticals
AVDL
$8.24M 9.99%
+500,000
New +$6.5M
HOOK
4
DELISTED
HOOKIPA Pharma
HOOK
$4.86M 5.89%
551,739
+521,739
+1,739% +$5.79M
APLT
5
DELISTED
Applied Therapeutics
APLT
$4.42M 5.35%
3,450,000
VRNA
6
DELISTED
Verona Pharma
VRNA
$4.23M 5.13%
200,000
GDX icon
7
VanEck Gold Miners ETF
GDX
$28.3B
$2.77M 3.35%
91,850
SIL icon
8
Global X Silver Miners ETF NEW
SIL
$4.95B
$2.33M 2.83%
89,700
ENTX icon
9
Entera Bio
ENTX
$488M
$2.09M 2.54%
2,484,275
GDXJ icon
10
VanEck Junior Gold Miners ETF
GDXJ
$8.96B
$1.9M 2.3%
53,150
BAH icon
11
Booz Allen Hamilton
BAH
$9.52B
$1.45M 1.76%
13,000
V icon
12
Visa
V
$701B
$1.15M 1.4%
4,850
TMO icon
13
Thermo Fisher Scientific
TMO
$227B
$1.1M 1.33%
2,100
OCUL icon
14
Ocular Therapeutix
OCUL
$2.35B
$1.03M 1.25%
200,000
MO icon
15
Altria Group
MO
$118B
$1.03M 1.25%
22,700
CVS icon
16
CVS Health
CVS
$122B
$1M 1.22%
14,500
FNV icon
17
Franco-Nevada
FNV
$51.3B
$998K 1.21%
7,000
SILV
18
DELISTED
SilverCrest Metals Inc. Common Shares
SILV
$996K 1.21%
170,000
NOC icon
19
Northrop Grumman
NOC
$74.9B
$987K 1.2%
2,165
OR icon
20
OR Royalties Inc
OR
$6.75B
$969K 1.17%
400,000
OMGA
21
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$969K 1.17%
173,010
SA
22
Seabridge Gold
SA
$3.19B
$964K 1.17%
80,000
OCUL icon
23
CALL
Ocular Therapeutix
OCUL
$2.35B
$814K 0.99%
95,800
ALT icon
24
Altimmune
ALT
$642M
$614K 0.74%
173,864
IRD
25
Opus Genetics
IRD
$497M
$434K 0.53%
100,000

Similar funds

Knoll Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Knoll Capital Management held 28 positions worth $82.5M, up 27% from $64.9M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Knoll Capital Management deployed $22.3M of net new capital in Q2 2023, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Avadel Pharmaceuticals: 500,000 shares worth $8.24M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Materials.

  • Knoll Capital Management's largest Q2 2023 buy was Avadel Pharmaceuticals: 500,000 shares worth $8.24M.
  • Knoll Capital Management added most to Aldeyra Therapeutics in Q2 2023, an estimated $9.35M increase.
  • Knoll Capital Management's ten largest holdings make up 81% of its $82.5M portfolio in Q2 2023.
  • Knoll Capital Management opened 2 new positions and closed 1 in Q2 2023.
  • Knoll Capital Management's portfolio value rose 27% quarter-over-quarter to $82.5M.

Based on Knoll Capital Management's 13F filing for Q2 2023, filed 15 Aug 2023.